학술논문
Real-world data of osimertinib (osi) for the treatment of metastatic epidermal growth factor receptor (EGFR plus ) nonsmall cell lung cancer (NSCLC) patients (pts), with a focus on age, body mass index (BMI) and trough levels
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
15698041